Top-Rated StocksTop-Rated DexCom Stock Price, News & Analysis (NASDAQ:DXCM) $117.72 +1.10 (+0.94%) (As of 01:59 PM ET) Add Compare Share Share Today's Range$116.20▼$117.7250-Day Range$75.49▼$116.6252-Week Range$74.75▼$139.55Volume1.26 million shsAverage Volume3.37 million shsMarket Capitalization$45.48 billionP/E Ratio129.36Dividend YieldN/APrice Target$130.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside13.3% Upside$132.33 Price TargetShort InterestHealthy4.59% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.21Based on 14 Articles This WeekInsider TradingSelling Shares$783,000 Sold Last QuarterProj. Earnings Growth18.18%From $1.43 to $1.69 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.92 out of 5 starsMedical Sector29th out of 952 stocksMedical Devices Industry1st out of 6 stocks 3.5 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $132.33, DexCom has a forecasted upside of 13.3% from its current price of $116.78.Amount of Analyst CoverageDexCom has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.59% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 15.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 2.9 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for DexCom this week, compared to 8 articles on an average week.Search InterestOnly 38 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $783,000.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions93.88% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 18.18% in the coming year, from $1.43 to $1.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 128.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 109.02.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 128.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 94.34.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.42. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 21.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesNovember 30, 2023 | finance.yahoo.com11 Best Long Term Growth Stocks To Invest InNovember 29, 2023 | benzinga.comDexCom Stock (NASDAQ:DXCM) Insider TradesDecember 4, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 28, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Director Steven Robert Pacelli Sells 411 SharesNovember 26, 2023 | americanbankingnews.comSadie Stern Sells 1,176 Shares of DexCom, Inc. (NASDAQ:DXCM) StockNovember 25, 2023 | finance.yahoo.comInsider Sell: EVP Chief Human Resources Officer Sadie Stern Sells Shares of DexCom Inc (DXCM)November 24, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Forecasted to Post FY2024 Earnings of $1.74 Per ShareNovember 23, 2023 | finance.yahoo.comHere's Why You Should Retain Edward Lifesciences (EW) Stock NowDecember 4, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Enanta Pharmaceuticals (ENTA) and Arvinas Holding Company (ARVN)November 22, 2023 | finance.yahoo.comDexCom's (NASDAQ:DXCM) 29% CAGR outpaced the company's earnings growth over the same five-year periodNovember 20, 2023 | finance.yahoo.comDexCom (DXCM) is an Incredible Growth Stock: 3 Reasons WhyNovember 20, 2023 | insidermonkey.comInvestors’ Concerns over the Impact of GLP-1 Drugs Dragged DexCom (DXCM)November 19, 2023 | finance.yahoo.com2 Stock Split Growth Stocks to Buy and HoldNovember 17, 2023 | msn.comReasons to Add DexCom (DXCM) Stock to Your Portfolio NowNovember 17, 2023 | finance.yahoo.comObesity Drugs Put These Stocks on a Crash Diet—Now They’re ReboundingNovember 14, 2023 | nasdaq.comDexcom Rings the Opening BellNovember 14, 2023 | finance.yahoo.comDexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes DayNovember 14, 2023 | finance.yahoo.comHenry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance CutNovember 13, 2023 | msn.comMedTech stocks gain after Novo Nordisk data for weight loss therapyNovember 9, 2023 | finance.yahoo.comInspire Medical (INSP) Q3 Earnings Top Estimates, Revenues LagNovember 9, 2023 | finance.yahoo.comSurmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/YNovember 8, 2023 | finanznachrichten.deDexCom, Inc.: Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don't Understand the Benefits1-2November 8, 2023 | finance.yahoo.comHistoric Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2November 2, 2023 | msn.comWhy DexCom (DXCM) Might be Well Poised for a SurgeNovember 2, 2023 | msn.comWall Street Analysts Think DexCom (DXCM) Could Surge 36.81%: Read This Before Placing a BetNovember 2, 2023 | finance.yahoo.comMcKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS ViewSee More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees7,500Year Founded1999Price Target and Rating Average Stock Price Target$130.93 High Stock Price Target$160.00 Low Stock Price Target$100.00 Potential Upside/Downside+12.3%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$0.91 Trailing P/E Ratio128.16 Forward P/E Ratio81.55 P/E Growth2.42Net Income$341.20 million Net Margins11.08% Pretax Margin17.56% Return on Equity25.05% Return on Assets8.99% Debt Debt-to-Equity Ratio1.07 Current Ratio2.80 Quick Ratio2.50 Sales & Book Value Annual Sales$2.91 billion Price / Sales15.49 Cash Flow$1.31 per share Price / Cash Flow89.04 Book Value$5.52 per share Price / Book21.13Miscellaneous Outstanding Shares386,370,000Free Float384,790,000Market Cap$45.06 billion OptionableOptionable Beta1.22 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 65)Executive Chairman, CEO & President Comp: $2.22MMr. Jereme M. Sylvain (Age 43)Executive VP, CFO & Chief Accounting Officer Comp: $841.14kMr. Jacob Steven Leach (Age 45)Executive VP & COO Comp: $994.13kMr. Girish Naganathan (Age 46)Executive VP & CTO Comp: $423.92kMr. Michael Jon Brown (Age 53)Executive VP & Chief Legal Officer Comp: $954.46kMr. Shelly Ramasamy Selvaraj (Age 64)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 42)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Sadie M. Stern (Age 48)Executive VP & Chief Human Resources Officer Mr. Steven R. Pacelli (Age 51)Executive VP & MD of Dexcom Ventures Comp: $873.62kMore ExecutivesKey CompetitorsResMedNYSE:RMDBaxter InternationalNYSE:BAXBecton, Dickinson and CompanyNYSE:BDXInsuletNASDAQ:PODDBoston ScientificNYSE:BSXView All CompetitorsInsiders & InstitutionsPhoenix Holdings Ltd.Sold 1,912 shares on 12/4/2023Ownership: 0.003%B. Riley Wealth Advisors Inc.Sold 37,698 shares on 12/1/2023Ownership: 0.001%Alamar Capital Management LLCBought 2,139 shares on 11/29/2023Ownership: 0.006%Banque Pictet & Cie SABought 75,848 shares on 11/27/2023Ownership: 0.045%Steven Robert PacelliSold 411 sharesTotal: $45,538.80 ($110.80/share)View All Insider TransactionsView All Institutional Transactions Should I Buy DexCom Stock? DXCM Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of DexCom was last updated on Tuesday, November 28, 2023 at 10:07 AM. Pros Here are some ways that investors could benefit from investing in DexCom, Inc.: DexCom, Inc. specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. With the increasing prevalence of diabetes, there is a growing demand for CGM systems to help patients manage their blood sugar levels. DexCom's products, such as the Dexcom G6 and Dexcom G7, offer real-time, continuous data on glucose levels, providing valuable insights for diabetes management. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. This partnership could lead to innovative advancements in CGM technology. DexCom's Dexcom Real-Time API enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This opens up opportunities for partnerships and integrations with other healthcare technology companies. Investors may find the current stock price of DexCom, Inc. attractive. Please note that the stock price is subject to market fluctuations and should be evaluated based on recent periods. Cons Investors should be bearish about investing in DexCom, Inc. for these reasons: The surgical and medical instruments industry, in which DexCom operates, can be highly competitive. The company may face challenges from existing competitors or new entrants in the market. While DexCom's CGM systems offer valuable data for diabetes management, the adoption of these systems may vary among healthcare providers and individuals with diabetes. Market acceptance and penetration could impact the company's growth potential. As with any medical device company, DexCom is subject to regulatory approvals and compliance. Changes in regulations or delays in obtaining approvals could affect the company's ability to bring new products to market. Investors should consider the financial performance and stability of DexCom, Inc. before making investment decisions. It is important to analyze the company's revenue growth, profitability, and cash flow to assess its long-term sustainability. Market conditions and macroeconomic factors can also impact the performance of DexCom, Inc. Investors should stay informed about industry trends, healthcare policies, and economic indicators that may affect the company's prospects. DXCM Stock Analysis - Frequently Asked Questions Should I buy or sell DexCom stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price target for 2024? 15 equities research analysts have issued 12-month price objectives for DexCom's stock. Their DXCM share price targets range from $100.00 to $160.00. On average, they expect the company's stock price to reach $130.93 in the next year. This suggests a possible upside of 11.8% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2023? DexCom's stock was trading at $113.24 at the beginning of 2023. Since then, DXCM stock has increased by 3.4% and is now trading at $117.08. View the best growth stocks for 2023 here. Are investors shorting DexCom? DexCom saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 17,750,000 shares, a drop of 15.7% from the October 31st total of 21,060,000 shares. Based on an average trading volume of 5,150,000 shares, the short-interest ratio is presently 3.4 days. View DexCom's Short Interest. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our DXCM earnings forecast. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Thursday, October, 26th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.16. The medical device company earned $975 million during the quarter, compared to analysts' expectations of $939.64 million. DexCom had a net margin of 11.08% and a trailing twelve-month return on equity of 25.05%. The business's quarterly revenue was up 26.7% on a year-over-year basis. During the same period last year, the company posted $0.28 EPS. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS). When did DexCom's stock split? DexCom's stock split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). Who are DexCom's major shareholders? DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.32%), Sands Capital Management LLC (3.54%), Blair William & Co. IL (1.17%), Jennison Associates LLC (1.11%), Northern Trust Corp (1.01%) and Clearbridge Investments LLC (0.84%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More This page (NASDAQ:DXCM) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.